Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis
E. S. Kuvardin,
D. Yu. Andreev,
P. A. Yastrebov,
V. Yu. Myachikova,
D. V. Bukhanova,
D. V. Karpova,
K. N. Malikov,
M. Yu. Samsonov,
A. L. Maslyanskiy https://doi.org/10.47360/1995-4484-2022-603-608
Abstract
Treatment algorithms for systemic sclerosis have not been completely developed. Effectivity of medications are usually used in clinical practice has a low level of evidence. Therefore, it is necessary to find a new treatment approaches for this nosological form. In the paper described clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis with interstitial lung disease, polyserositis, severe microcirculatory alterations.
About the Authors
E. S. Kuvardin
Almazov National Medical Research Centre
Russian Federation
Russian Federation
197341, Saint Petersburg, Akkuratova str., 2
D. Yu. Andreev
Clinic of Esthetic Medicine and Digital Dentistry MEDALL
Russian Federation
Russian Federation
197110, Saint Petersburg, Levashovsky avenue, 24
P. A. Yastrebov
Clinic of Esthetic Medicine and Digital Dentistry MEDALL
Russian Federation
Russian Federation
197110, Saint Petersburg, Levashovsky avenue, 24
V. Yu. Myachikova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
197341, Saint Petersburg, Akkuratova str., 2
D. V. Bukhanova
R-Pharm Group
Russian Federation
Russian Federation
119421,Moscow, Leninsky avenue, 111, korpus 1
D. V. Karpova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
197341, Saint Petersburg, Akkuratova str., 2
K. N. Malikov
Almazov National Medical Research Centre
Russian Federation
Russian Federation
197341, Saint Petersburg, Akkuratova str., 2
M. Yu. Samsonov
R-Pharm Group
Russian Federation
Russian Federation
119421,Moscow, Leninsky avenue, 111, korpus 1
A. L. Maslyanskiy
Almazov National Medical Research Centre; Saint-Petersburg State University
Russian Federation
Russian Federation
197341, Saint Petersburg, Akkuratova str., 2
199034, Saint Petersburg, Universitetskaya embankment, 7–9
References
1. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755. doi:10.1136/annrheumdis-2013-204424
2. Park EH, Strand V, Oh YJ, Song YW, Lee EB. Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study. Arthritis Res Ther. 2019;21(1):61. Published 2019 Feb 15. doi:10.1186/s13075-019-1842-x
3. van Leeuwen NM, Ciaffi J, Liem SIE, et al. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology (Oxford). 2021;60(8):3646– 3655. doi:10.1093/rheumatology/keaa827
4. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017; 390(10103):1685–1699. doi:10.1016/S0140-6736(17)30933-9
5. Yen EY, Singh DR, Singh RR. Trends in Systemic Sclerosis Mortality Over Forty-Eight Years, 1968–2015: A US Population-Based Study. Arthritis Care Res (Hoboken). 2021;73(10):1502–1510. doi:10.1002/acr.24411
6. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. doi:10.1136/annrheumdis-2016-209909
7. Naidu GSRSNK, Sharma SK, Adarsh MB, et al. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a doubleblind, placebo-controlled, randomized trial. Rheumatol Int. 2020;40(2):207–216. doi:10.1007/s00296-019-04481-8
8. Ананьева Л.П. Современная терапия интерстициальных пневмоний, ассоциированных с системной склеродермией. Научно-практическая ревматология. 2020;58(5):520–531.
9. Bruni T, Varone F. The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe (Sheff). 2020;16(2):200005. doi:10.1183/20734735.0005-2020
10. de Figueiredo Caldas MMV, de Azevedo KPM, de França Nunes AC, et al. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis. Adv Rheumatol. 2021;61(1):15. Published 2021 Feb 27. doi:10.1186/s42358-021-00170-y
11. Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial [published correction appears in Lancet. 2018 Apr 7;391(10128):1356]. Lancet. 2016;387(10038):2630–2640. doi:10.1016/S0140-6736(16)00232-4
12. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Respir Med. 2020 Oct;8(10):e75] [published correction appears in Lancet Respir Med. 2021 Mar;9(3):e29]. Lancet Respir Med. 2020;8(10):963–974. doi:10.1016/S2213-2600(20)30318-0
13. Невская Т.А., Новиков А.А., Александрова Е.Н., Мач Э.С., Запрягаева М.Н., Сперанский А.И., Гусева Н.Г., Ананьева Л.П. Клиническое значение высокочувствительного С-реактивного белка при системной склеродермии. Научно-практическая ревматология. 2007;45(4):10–17.
14. Cardonea nu A, Burlui AM, Macovei LA, et al.. Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?. Biomedicines. 2022;10(2):318. Published 2022 Jan 29. doi:10.3390/biomedicines10020318
15. Ananyeva LP Prospects for using tocilizumab in systemic sclerosis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):632–40 (In Russ.). doi: 10.14412/1995-4484-2015-632-640
16. Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?. BioDrugs. 2018;32(6):531–546. doi:10.1007/s40259-018-0320-3
17. Hosoya H, Derk CT. Clinically Symptomatic Pericardial Effusions in Hospitalized Systemic Sclerosis Patients: Demographics and Management. Biomed Res Int. 2018;2018:6812082. Published 2018 Jun 4. doi:10.1155/2018/6812082
18. Ufuk F, Çakmak P, Sağtaş E, et al. Extra-parenchymal chest HRCT findings of patients with systemic sclerosis at the time of initial diagnosis. Bezmialem Science. 2018;7(2):101–106. doi:10.14235/bs.2018.2427
19. Ocampo V, Haaland D, Legault K, et al.. Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a pa - tient with systemic lupus erythematous. BMJ Case Rep. 2016;2016: bcr2016215423. Published 2016 Aug 8. doi:10.1136/bcr-2016-215423
20. Yoshida S, Takeuchi T, Sawaki H, et al. Successful treatment with tocilizumab of pericarditis associated with rheumatoid arthritis. Mod Rheumatol. 2014;24(4):677–680. doi:10.3109/14397595.2013.874733
21. Zacay G, Levy Y. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. Best Pract Res Clin Rheumatol. 2018;32(4):563–571. doi:10.1016/ j.berh.2019.01.011
22. Kawaguchi Y. Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis. Journal of Scleroderma and Related Disorders. 2017;2(2):6–12. doi:10.5301/jsrd.5000258
23. Hernández-Sánchez J, Harlow L, Church C, et al. Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hyperten - sion. Pulm Circ. 2018;8(1):2045893217735820. doi:10.1177/ 2045893217735820
Review
For citations:
Kuvardin E.S., Andreev D.Yu., Yastrebov P.A., Myachikova V.Yu., Bukhanova D.V., Karpova D.V., Malikov K.N., Samsonov M.Yu., Maslyanskiy A.L. Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis. Rheumatology Science and Practice. 2022;60(5):603-608. (In Russ.) https://doi.org/10.47360/1995-4484-2022-603-608
Views:
387
Email this article 